TY - JOUR
T1 - A plasmonic nanoparticle-embedded polydopamine substrate for fluorescence detection of extracellular vesicle biomarkers in serum and urine from patients with systemic lupus erythematosus
AU - Zhou, Ze Rui
AU - Chen, Xia
AU - Lv, Jian
AU - Li, Da Wei
AU - Yang, Cheng De
AU - Liu, Hong Lei
AU - Qian, Ruo Can
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - There is an unmet clinical need to develop noninvasive liquid biopsy tools for systemic lupus erythematosus (SLE) diagnosis and therapeutic effect evaluation. Extracellular vesicles (EVs), which are abundant in body fluids, have emerged as a valuable resource for liquid biopsy. Herein, we describe a simple and robust EV detection platform that is based on a plasmonic nanoparticle-embedded polydopamine substrate that is modified with EV-capture molecules and detection probes. We investigated three EV biomarkers, namely, programmed cell death protein-1 (PD-1), microRNA-146a (miRNA-146a) and sialic acid (SA), in serum and urine from SLE patients and healthy controls. This platform prevents complex pretreatment while enabling highly efficient EV capture to the substrate surface, and the multiple functionalization of the detection interface with specific biomarker probes enables simultaneous detection of PD-1, miRNA-146a and SA that are carried by EVs via fluorescence (FL) imaging at the single-vesicle level. Via comparison of EV biomarker profiles, SLE patients can be distinguished from normal controls and classified into treated and untreated groups. Due to its ease of preparation, simplicity and stability, our approach shows good potential in the design of EV-based biosensors for clinical use.
AB - There is an unmet clinical need to develop noninvasive liquid biopsy tools for systemic lupus erythematosus (SLE) diagnosis and therapeutic effect evaluation. Extracellular vesicles (EVs), which are abundant in body fluids, have emerged as a valuable resource for liquid biopsy. Herein, we describe a simple and robust EV detection platform that is based on a plasmonic nanoparticle-embedded polydopamine substrate that is modified with EV-capture molecules and detection probes. We investigated three EV biomarkers, namely, programmed cell death protein-1 (PD-1), microRNA-146a (miRNA-146a) and sialic acid (SA), in serum and urine from SLE patients and healthy controls. This platform prevents complex pretreatment while enabling highly efficient EV capture to the substrate surface, and the multiple functionalization of the detection interface with specific biomarker probes enables simultaneous detection of PD-1, miRNA-146a and SA that are carried by EVs via fluorescence (FL) imaging at the single-vesicle level. Via comparison of EV biomarker profiles, SLE patients can be distinguished from normal controls and classified into treated and untreated groups. Due to its ease of preparation, simplicity and stability, our approach shows good potential in the design of EV-based biosensors for clinical use.
KW - Extracellular vesicle
KW - Liquid biopsy
KW - Plasmonic nanoparticle
KW - Polydopamine
KW - Systemic lupus erythematosus
UR - https://www.scopus.com/pages/publications/85131118461
U2 - 10.1016/j.talanta.2022.123620
DO - 10.1016/j.talanta.2022.123620
M3 - 文章
C2 - 35649328
AN - SCOPUS:85131118461
SN - 0039-9140
VL - 247
JO - Talanta
JF - Talanta
M1 - 123620
ER -